WO2006044762A3 - Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor - Google Patents

Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor Download PDF

Info

Publication number
WO2006044762A3
WO2006044762A3 PCT/US2005/037193 US2005037193W WO2006044762A3 WO 2006044762 A3 WO2006044762 A3 WO 2006044762A3 US 2005037193 W US2005037193 W US 2005037193W WO 2006044762 A3 WO2006044762 A3 WO 2006044762A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pyrimido
tetrahydro
ht2c receptor
diseases associated
Prior art date
Application number
PCT/US2005/037193
Other languages
French (fr)
Other versions
WO2006044762A2 (en
Inventor
Ann-Marie Campbell
Philip Coish
Stephen O'connor
Evelyn Sibley
Harold Wright
Ming Wang
Donald Bierer
Original Assignee
Bayer Pharmaceuticals Corp
Ann-Marie Campbell
Philip Coish
Stephen O'connor
Evelyn Sibley
Harold Wright
Ming Wang
Donald Bierer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Ann-Marie Campbell, Philip Coish, Stephen O'connor, Evelyn Sibley, Harold Wright, Ming Wang, Donald Bierer filed Critical Bayer Pharmaceuticals Corp
Publication of WO2006044762A2 publication Critical patent/WO2006044762A2/en
Publication of WO2006044762A3 publication Critical patent/WO2006044762A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to tetrahydro-5H-pyrimido[4,5-d]azepine compounds of Formula (I) that are useful in the treatment or prevention of diseases and/or behaviors that involve the 5-HT2C receptor. The compounds of the present invention may also be used for the treatment or prevention of diseases and/or disorders including obesity, obesity-related disorders such as diabetes, feeding behavior disorders, eating disorders such as bulimia and anorexia nervosa, and premenstrual tension.
PCT/US2005/037193 2004-10-15 2005-10-14 Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor WO2006044762A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61919504P 2004-10-15 2004-10-15
US60/619,195 2004-10-15

Publications (2)

Publication Number Publication Date
WO2006044762A2 WO2006044762A2 (en) 2006-04-27
WO2006044762A3 true WO2006044762A3 (en) 2006-08-03

Family

ID=36203607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/037193 WO2006044762A2 (en) 2004-10-15 2005-10-14 Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor

Country Status (1)

Country Link
WO (1) WO2006044762A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080145A1 (en) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv TETRAHYDRO-PYRIMIDOAZEPINE AS MODULATORS OF TRPV1
WO2007132841A1 (en) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
JP2010522156A (en) * 2007-03-23 2010-07-01 ファイザー・リミテッド Pyrimido [4,5-d] azepine derivatives as 5-HT2c agonists
WO2009063992A1 (en) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited Condensed pyridine derivative and use thereof
CL2008003749A1 (en) 2007-12-17 2010-01-15 Janssen Pharmaceutica Nv Compounds derived from imidazole, oxazole, and pyrimidine thiazole, trpv1 modulators, preparation process, pharmaceutical composition and their use in the treatment of diseases, disorders or conditions of pain, pruritus, arthritis, cough, asthma, inner ear disorder and disease inflammatory bowel, among others.
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JPWO2019131902A1 (en) 2017-12-27 2020-12-10 武田薬品工業株式会社 Remedies for stress urinary incontinence and fecal incontinence
KR20210049135A (en) * 2018-08-24 2021-05-04 재규어 테라퓨틱스 피티이 리미티드 Tetrahydropyridopyrimidine derivatives as modulators
WO2021173082A1 (en) * 2020-02-26 2021-09-02 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021844A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc 5ht2b receptor antagonists condensed indoles
US20030225057A1 (en) * 2002-04-12 2003-12-04 Arena Pharmaceuticals, Inc. 5HT2c receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021844A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc 5ht2b receptor antagonists condensed indoles
US20030225057A1 (en) * 2002-04-12 2003-12-04 Arena Pharmaceuticals, Inc. 5HT2c receptor modulators

Also Published As

Publication number Publication date
WO2006044762A2 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
WO2006044762A3 (en) Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
WO2006014618A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
WO2006020959A3 (en) Substituted benzofused heterocycles
MXPA05013366A (en) Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases.
WO2005080343A3 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
DE602006005477D1 (en) Imidazopyridinverbindungen
WO2003028641A3 (en) Mch receptor antagonists
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
IL191629A0 (en) Tricyclic amide derivatives useful for treating obesity
PT1960352E (en) 2-adamantylurea derivatives as selective 11beta-hsd1 inhibitors
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
WO2007124337A8 (en) Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1
TW200621716A (en) Novel compounds
WO2007059257A8 (en) N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
WO2004050039A3 (en) Spirocyclic ureas, compositions containing such compounds and methods of use
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
WO2005080345A3 (en) Imidazoline derivatives having cb1-antagonistic activity
WO2007145835A3 (en) Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
GB0513886D0 (en) Novel compounds
HK1068622A1 (en) Novel heteroaryl derivatives, their preparation and use
WO2006044753A3 (en) Chemical compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05815538

Country of ref document: EP

Kind code of ref document: A2